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Abstract 
Background: Human adenovirus (HAdV) infections remain a significant cause of morbidity and mortality after 
hematopoietic stem cell transplantation (HSCT). Efficient antiviral T‑cell responses are necessary to clear infection, 
which is hampered by delayed immune reconstitution and medical immunosuppression after HSCT. Protective immu‑
nity may be conferred by adoptive transfer of HAdV‑specific T cells. For identification of patients at risk and monitor‑
ing of treatment responses diligent assessment of anti‑HAdV cellular immune responses is crucial. The HAdV‑derived 
protein hexon has been recognized as a major immunodominant target across HAdV species. We aimed at identifying 
further targets of protective anti‑HAdV immune response and characterizing immunogenic epitopes.
Methods: Nineteen candidate nonamers from hexon and penton proteins were identified by epitope binding 
prediction. Peptides were synthesized and tested for in vivo immunogenicity by screening peripheral blood mono‑
nuclear cells from healthy volunteers (n = 64) and HAdV‑infected stem cell recipients (n = 26) for memory T cells 
recognizing the candidate epitopes in the context of most common HLA alleles.
Results: Functional CD8+ T cells recognizing seven epitopes were identified, among them four penton‑derived and 
two hexon‑derived peptides. The HLA‑A*01‑restricted penton‑derived peptide STDVASLNY (A01PentonSTDV) and HLA‑
A*02‑restricted hexon‑derived peptide TLLYVLFEV (A02HexonTLLY) were recognized by more than half of the persons 
carrying the respective HLA‑type.
Conclusions: Thus, the HAdV‑derived penton protein is a novel major target of the anti‑HAdV immune response. 
Identification of new immunodominant epitopes will facilitate and broaden immune assessment strategies to identify 
patients suitable for T‑cell transfer. Knowledge of additional target structures may increase T‑cell recovery in manufac‑
turing processes.
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Background
Human adenovirus (HAdV) infection constitutes a major 
cause of morbidity and mortality in patients undergoing 
allogeneic hematopoietic stem cell transplantation 
(HSCT). The incidence of HAdV infection ranges from 
5 to 30 %, with pediatric recipients showing the highest 
rates of infection with up to 83 % lethality [1–6]. Moni-
toring for HAdV infection and therapeutic intervention 
(reduction of immunosuppression, antiviral treatment) 
may reduce mortality due to HAdV in pediatric HSCT 
recipients [7]. However, antiviral treatments for HAdV 
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associated with toxicity and may result in delayed 
immune reconstitution. Previous studies clearly indi-
cate that T cells, the most potent effectors of the human 
immune system, are crucial for HAdV clearance [2]. It 
was demonstrated that children with HAdV-associated 
mortality had no HAdV-specific T cells, whereas patients 
who cleared HAdV infection showed HAdV-specific 
T-cell responses [2, 8]. Adoptive transfer of HAdV-
specific T cells offers an effective and non-toxic immu-
notherapeutic strategy to reduce or prevent the clinical 
manifestation of HAdV in HSCT recipients with no or 
low numbers of HAdV-specific T cells [2, 8–12]. Moni-
toring HAdV-specific T-cell immunity may improve risk 
assessment in HSCT recipients and enhance treatment 
efficacy by determining the optimal time point for adop-
tive T-cell transfer. The median time between the first 
detection of HAdV DNA in the blood and the onset of 
symptoms is 3  weeks, which therefore seems to be the 
optimal time point for adoptive T-cell transfer [2, 13, 
14]. Since the generation of short-term in vitro generated 
virus-specific T-cell lines takes about 3 weeks including 
quality controls, the production should start even earlier 
at the time of high viral load in stool (>106 copies) [12, 
15].
The 70 different human HAdV types identified to date 
are divided into seven species (A to G) [16, 17]. Type 31 
(of species HAdV-A) and HAdV 1, 2, and 5 (of species 
HAdV-C) are the most prevalent types in HSCT recipi-
ents [4–7]. Occasionally, types of species HAdV-B can 
be observed in adult HSCT recipients [18]. The major 
capsid protein hexon serves as an immunodominant 
target antigen across the different HAdV types, but few 
hexon-derived epitopes have been identified as immu-
nodominant so far [13, 19–23]. Most of these epitopes 
are highly conserved, demonstrating that HAdV-spe-
cific T cells can cross-react across HAdV species and 
may therefore provide protection against a wide range 
of HAdV types [20]. HAdV-specific T-cell responses to 
the recombinant hexon protein, the overlapping pep-
tide pool covering the complete hexon sequence, HLA-
restricted peptides, and whole viral lysates have been 
investigated. A study by Feuchtinger et al. revealed that 
10.5  % of donors had a specific T-cell response to the 
whole adenovirus but no response to the hexon protein, 
while 17 % of donors had no detectable T-cell response 
to HAdV [11]. Moreover, Zandvliet et al. detected spe-
cific CD8+ T cells in 6/16 healthy donors (37.5 %) after 
stimulation with the 15-mer hexon peptide pool, but 
only 3/16 donors (18.8 %) had specific T cells for known 
CD8+ hexon epitopes [24]. Sukdolak et  al. observed a 
specific T-cell response to the 15-mer hexon peptide 
pool in 73  % of HAdV seropositive healthy donors, 
while 30 % were classified as high responders and 43 % 
as low responders [25]. Interestingly, 27 % of all HAdV 
seropositive healthy donors tested showed no response 
to the hexon peptide pool. These results underline the 
need to identify more immunogenic T-cell epitopes 
to improve the selection of HAdV-specific T cells for 
adoptive transfer and the immunomonitoring of high-
risk patients.
T-cell epitopes can be identified by direct or reverse 
immunology. Various computer algorithms have been 
developed over the past years that allow for the predic-
tion of peptide binding to MHC class I and II molecules, 
proteasome cleavage patterns and transporter associated 
with antigen processing translocation [26]. Naturally pre-
sented CD8+ T-cell epitopes are usually among the top-
scoring 2 in 80 % of all predictions, whereas the reliability 
of CD4+ T-cell epitope prediction is much lower due 
to the more variable pocket binding behavior of MHC 
class II molecules [27]. SYFPEITHI [26, 28, 29], BIMAS 
[26, 30] and NetChop [31] are the most widely used 
algorithms to identify cytotoxic T lymphocyte (CTL) 
epitopes in viral, microbial, and tumor antigens. These 
well-established algorithms, which have been validated 
and compared [26], were employed in this study to pre-
dict new HAdV epitopes.
The major focus of this study was to identify and 
evaluate novel immunodominant HAdV-specific T-cell 
epitopes by analyzing the main structural proteins, 
hexon and penton. HLA-A*01-, A*02-, A*03- and B*08-
restricted peptide epitopes within conserved protein 
regions (Table  1) were pre-selected based on the pre-
dictions of several established computer algorithms. 
Immunogenicity of the top-ranked epitopes was inves-
tigated by established methods: IFN-γ-based EliSpot, 
cytokine secretion assay (CSA), peptide MHC (pMHC) 
multimer staining and multicolor flow cytometry. Four 
of the selected peptide candidates were classified as low 
immunodominant and two as high immunodominant 
according to the number of responders in the healthy 
donors and HAdV-infected HSCT recipients. This paper 
describes for the first time the immunogenic potential of 
penton-derived epitopes and demonstrates that the pen-
ton, as an immunological target, it is not secondary to the 
hexon. Expanding the repertoire of immunodominant 
HAdV-specific T-cell epitopes will enable more precise 
immunomonitoring and more effective multi-epitope-
based T-cell therapy by targeting epitopes presented in a 
broader array of HLA molecules.
Methods
Study population
The current study has been approved by the Internal 
Review Board of Hannover Medical School. Following 
written informed consent peripheral blood was obtained 
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from 64 healthy platelet donors from the Hannover 
Medical School (MHH) Institute for Transfusion Medi-
cine and 26 pediatric patients after HSCT with detect-
able HAdV-DNA in blood and/or stool. Healthy donors 
had no prior history of blood transfusion and no signs 
of acute infection. All donors and patients were typed 
for HLA class I and class II alleles at the four-digit level 
by sequence-based typing [32]. Informed consent was 
obtained from all donors and patients as approved by 
the Ethics Committee of Hannover Medical School, and 
trial subject data were treated as confidential information 
protected by medical confidentiality.
Epitope prediction
HAdV hexon and penton protein sequences restricted 
to the types 1, 2, 3, 5, and 31 were obtained from the 
SwissProt database (http://www.uniprot.org). Epitope 
prediction programs SYFPEITHI (http://www.syfpeithi.
de) [28, 29], BIMAS (http://www.bimas.cit.nih.gov) [30], 
and NetChop (http://www.cbs.dtu.dk) [31] were used to 
predict nonamers capable of binding to HLA- A*01:01, 
A*02:01, A*03:01 and B*08:01 molecules (Fig. 1). Epitope 
candidates were only selected if identified by all programs 
according to their predictive scores (Table  1). The NET-
MHCSTAB [33], NETMHC, and NETMHCcons (Fig. 1) pre-
diction algorithms provided by the Center for Biological 
Sequence Analysis (CBS, http://www.cbs.dtu.dk) was 
used to predict the stability of pMHC complexes for all 
database-available HLA types.
Synthetic peptides and peptide pools
Peptides of the 19 top-scoring epitope candidates 
(Table  1) were synthesized (China Peptides, Shang-
hai, China; ProImmune, Oxford, UK) and used for 
pre-screening and T-cell immunoassays (Fig.  1). The 
overlapping peptide pools of hexon (HAdV5Hexonpp, 
Miltenyi Biotec, Bergisch Gladbach) and penton (HAd-
V5Pentonpp, Miltenyi Biotec) were further used as stimuli 
of antiviral memory T cells. The HLA-A*01-restricted 
hexon-derived peptide TDLGQNLLY (A01HexonTDLG, 
ProImmune, Table  1) was used as a positive control. 
Peptide binding assays were performed using two addi-
tional HLA-restricted peptides from phosphoprotein 65 
(pp65) of the human cytomegalovirus (YSEHPTFTSQY: 
A01pp65YSEH and NLVPMVATV: A02pp65NLVP, ProIm-
mune) as positive controls.
Table 1 Predicted peptide candidates used for HAdV-specific T-cell screening in healthy donors
Names, sequences and abbreviations of 19 epitope candidates (plus one reference epitope, A01HexonTDLG) predicted for frequent HLA class I alleles and clinically 
relevant HAdV types. The immunogenicity of epitope candidates was evaluated by pre-screening HAdV-specific T-cell responses to the 19 synthesized peptides in 
healthy donors using IFN-γ EliSpot assay. Seven of 19 peptide candidates induced HAdV-specific T-cell responses, six of which (highlighted in italic) were classified 
as immunodominant. The following epitope sequences were published elsewhere: A01HexonTDLG [13, 20, 21], A01HexonTNDQ [21], A02HexonTLLY [13, 22, 23], 
A02HexonTLAV [13], and B08HexonGLRY [20] (NA not applicable)





HLA‑A*01:01 TDLGQNLLY A01HexonTDLG C: 1, 2, 5 13/18 High [13, 20, 21]
HLA‑A*01:01 TNDQSFNDY A01HexonTNDQ A: 31, B: 3, C: 1, 2, 5 2/12 No [21]
HLA‑A*01:01 QNDPTVVMY A01HexonQNDP A: 31 0/8 NA
HLA‑A*02:01 TLLYVLFEV A02HexonTLLY A: 31, C:1, 2, 5 28/41 High [13, 22, 23]
HLA‑A*02:01 TLAVGDNRV A02HexonTLAV A: 31, B: 3, C: 1, 2, 5 0/5 No [13]
HLA‑B*08:01 GLRYRSMLL B08HexonGLRY A: 31, B: 3, C: 1, 2, 5 0/5 Minimal [20]
HLA‑B*08:01 DLQDRNTEL B08HexonDLQD A: 31, B: 3, C: 1, 2, 5 6/27 NA
HLA‑A*01:01 STDVASLNY A01PentonSTDV C: 1, 2, 5 25/38 NA
HLA‑A*01:01 SNDSTFTQY A01PentonSNDS C: 1, 2, 5 0/8 NA
HLA‑A*01:01 SSDIASLNY A01PentonSSDI A: 31 0/5 NA
HLA‑A*01:01 LTDHGTLPL A01PentonLTDH A: 31, B: 3, C: 1, 2, 5 0/5 NA
HLA‑A*02:01 ILHTNMPNV A02PentonILHT A: 31, C: 1, 2, 5 7/28 NA
HLA‑A*02:01 ALGIVSPRV A02PentonALGI A: 31, C: 1, 2, 5 0/6 NA
HLA‑A*02:01 GNIPALLDV A02PentonGNIP A: 31, B: 3, C: 1, 2, 5 0/6 NA
HLA‑A*03:01 VLESDIGVK A03PentonVLES A: 31, B: 3, C: 1, 2, 5 0/6 NA
HLA‑A*03:01 LLPGCGVDF A03PentonLLPG A: 31, B: 3, C: 1, 2, 5 0/6 NA
HLA‑B*08:01 NTKYRSWYL B08PentonNTKY A: 31 0/7 NA
HLA‑B*08:01 DSKGRSYNL B08PentonDSKG A: 31 9/36 NA
HLA‑B*08:01 LTKDKQVEL B08PentonLTKD C: 1, 2 0/5 NA
HLA‑B*08:01 DSKKRSYNL B08PentonDSKK C: 1, 2, 5 15/36 NA
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HLA class I peptide binding assay
The T2 peptide binding assay was performed with the 
HLA-A*01- and HLA-A*-02-restricted peptide candidates 
as described previously [34]. To determine peptide bind-
ing to HLA-A*01:01 molecules, T2 cells were transfected 
to express membrane-bound HLA-A*01:01 [35]. Briefly, 
1  ×  106 T2 cells/ml were pulsed with 50  μg/ml peptide 
(Table 1) and 5 μg/ml beta-2 microglobulin (β2 m, Sigma, 
St Louis, MO, US) in serum-free medium for 15–18 h at 
37  °C. T2 cells incubated without peptide served as con-
trols. HLA expression levels were determined by flow 
cytometry (FACSCanto II and FACSDiva V6.1.2 software, 
BD Biosciences, San Jose, CA) using the monoclonal anti-
bodies (mAb) HLA-ABC fluorescein (FITC, w6/32, AbD 
Serotec, Ltd-Kidlington, UK) and anti-HLA-A*02 phyco-
erythrin (PE, BB7.2, Biolegend, San Diego, CA, US).
Screening for HAdV peptide-specific HLA-restricted T cells
The IFN-γ EliSpot assay was used for peptide screening to 
enumerate HAdV-specific IFN-γ-producing T cells [25, 
36]. Briefly, peripheral blood mononuclear cells (PBMCs) 
were plated at a density of 2.5 × 105 cells/well in tripli-
cate wells and incubated overnight in the presence of the 
investigated peptides (10 µg/ml) and peptide pools (1 µg 
per peptide/ml). PBMCs cultured with medium alone or 
in the presence of 1 µg/ml staphylococcal enterotoxin B 
(SEB, Sigma-Aldrich, Hamburg, Germany) served as neg-
ative and positive controls, respectively. Spots of IFN-γ-
positive cells were counted and analyzed and the results 
were expressed as the number of spots per well (spw). 
The mean number of spots in the negative control was 
subtracted from the mean number of spots in the anti-
gen wells. The cut-off value for a positive response was 
≥5 spw in healthy donors and ≥2 spw in HAdV-infected 
patients.
T-cell proliferation assay
The proliferative capacities of HAdV-specific T cells 
induced by the various peptide candidates (Table 1, high-
lighted in italic) were analyzed by carboxyfluorescein 
RefSeq proteins from HAdV serotypes of interest
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Fig. 1 Schematic overview of the experimental approach for the identification and evaluation of novel CD8+ T‑cell epitopes. The identification and 
evaluation of epitope candidates were the two major steps of the general workflow. First, epitope candidates were mapped by reverse immunology 
using different prediction algorithms for peptide binding affinity and stability. Second, the highest‑scoring peptide candidates were synthesized 
and evaluated for immunogenicity by T‑cell pre‑screening and T‑cell immunoassay
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succinimidyl ester (CFSE) dilution assay (Invitro-
gen, Darmstadt, Germany). 5  ×  105  CFSE-labeled 
PBMCs were stimulated with 10  µg/ml peptide for 
7 days. Unstimulated T cells were used as negative con-
trols. Spontaneous T-cell proliferation in unstimu-
lated controls was subtracted from the specific values 
in peptide-stimulated cultures. Cells were stained with 
allophycocyanin (APC)-conjugated anti-CD8 mAb and 
PE-Cy7-conjugated anti-CD3 mAb (all BD Biosciences). 
The distribution of viable and dead cells was analyzed 
by 7-amino-actinomycin D (7-AAD) staining (BD Bio-
sciences). At least 50,000 events were acquired in the 
7-AAD− gate. CFSE+/−CD3+ and CFSE+/−CD8+ T-cell 
populations were gated based on the scatter proper-
ties of viable 7-AAD−CD3+ or 7-AAD−CD3+CD8+ T 
lymphocytes.
Immunophenotyping and detection of HAdV-specific T 
cells
A comprehensive analysis of the phenotype and specific-
ity of HAdV-specific T cells was performed with freshly 
isolated PBMCs and in vitro expanded HAdV-specific T 
cells. PBMCs from healthy donors were stimulated for 
7  days with 10  µg/ml peptide (Table  1, highlighted in 
italic), and restimulated for another 7  days with irradi-
ated autologous peptide-loaded PBMCs. Flow cytomet-
ric analysis of the CD8+ T-cell phenotype was performed 
using cells stained with the mAbs anti-CD3 peridinin 
chlorophyll protein (PerCP), anti-CD8 APC (BD Bio-
sciences), anti-CD19 FITC, anti-CD62L APC-Cy7, and 
anti-CD45RA PE-Cy7 (BioLegend) to assess the fre-
quencies of naïve T cells (TN; CD62L+ CD45RA+), cen-
tral memory T cells (TCM; CD62L+ CD45RA−), effector 
memory T cells (TEM; CD62L− CD45RA−), and ter-
minally differentiated effector memory T cells (TEMRA; 
CD62L− CD45RA+).
In addition, specificities and frequencies of CD8+ T 
cells against the peptide candidates A01PentonSTDV, 
A02HexonTLLY, and the positive control A01HexonTDLG 
(Table  1) were detected by pMHC multimer staining 
using R-PE-conjugated multimeric Pro5 pentamers (Pro-
Immune). At least 100,000 events were acquired in the 
lymphocyte gate, which was set based on the light scat-
ter properties scatter properties of lymphocytes and on 
CD3+ T-cell populations. To be considered positive, the 
sample had to (1) be a well-defined cell population and/
or (2) contain ≥0.3 % pentamer+CD8+ T cells.
Cytotoxic activity of peptide-induced HAdV-specific T cells
The cytotoxicity of in  vitro expanded peptide-specific 
T cells (day 14) was assessed in a non-radioactive flow 
cytometric assay using autologous CFSE-labeled pep-
tide-loaded PBMCs as target cells. In order to exclude 
alloreactivity, unloaded CFSE-labeled PBMCs were fur-
ther used as target cells, in which the basal cytotoxic 
activity of effector T cells against the unloaded target 
cells was subtracted from the specific cytotoxic values. 
Briefly, effector T cells were incubated with target cells at 
effector to target (E:T) ratios of 10:1, 30:1 and 60:1. Tar-
get cell lysis was assessed after 5 h using 7-AAD staining.
In addition, antiviral T-cell degranulation was deter-
mined as a surrogate marker of cytotoxicity by testing 
for CD107a cell surface expression by flow cytometry. 
In vitro expanded HAdV-specific T cells were incubated 
with 10  µg/ml peptide and PE-Cy7-conjugated anti-
CD107a mAb (BioLegend) at 37  °C and 5  % CO2. After 
1  h of incubation, monensin (1:1000, BioLegend) was 
added and cells were incubated for further 4  h before 
staining with anti-CD3 PerCP and anti-CD8 APC.
Enrichment of HAdV peptide-specific T cells
The enrichment efficiency of in  vitro expanded HAdV 
peptide-specific T cells (day 14) was assessed using the 
cytokine secretion assay (Miltenyi Biotec). Aliquots of 
cell fractions before enrichment (“Origin”) and after 
enrichment (“Eluate”) were used for detailed analysis 
of IFN-γ-secreting viable HAdV-specific T-cell subsets 
by multicolor flow cytometry. In addition to anti-IFN-γ 
PE (Miltenyi Biotec), cells were stained with anti-CD45 
APC-Cy7, anti-CD56 PE-Cy7, anti-CD3 FITC, anti-CD8-
APC mAbs, and 7-AAD (all BD Biosciences). At least 
10,000 events were acquired in the viable CD45+7AAD− 
leukocyte gate.
Statistical analysis
Statistical analysis was performed using the Prism v5.02 
software (GraphPad, San Diego, California, USA). The 
results are displayed as mean ± standard deviation (SD). 
Generated data were analyzed using non-parametric 
Mann–Whitney U test. Significance levels were cal-
culated and expressed as p values (*p < 0.05, **p < 0.01, 
***p < 0.001).
Results
Selection of potential HLA-restricted peptide epitopes 
within hexon and penton protein
A total of 947 hexon- and penton-derived epitope can-
didates restricted to HLA-types A*01, A*02, A*03, and 
B*08 were identified by the computer algorithms SYF-
PEITHI, BIMAS, and NetChop (Fig. 1). Nineteen (2 %) 
of the highest scoring sequences (six HLA-A*01-, five 
HLA-A*02-, two HLA-A*03-, and six HLA-B*08-res-
ticted peptides; Table  2, [13, 20–23]) were synthesized. 
All three algorithms yielded comparably high prediction 
scores for seven of the 19 peptide epitopes (A02Hex-
onTLLY, B08HexonGLRY, A01PentonSTDV, A01PentonSSDI, 
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A02PentonILHT, B08PentonNTKY, and B08PentonDSKK): 
the SYFPEITHI score was 23–35, the BIMAS rank 1–2, 
and NetChop rating “strong binder (SB)” (Table  2). In 
comparison to the known immunodominant peptide 
epitopes of HAdV (A01HexonTDLG) and of cytomeg-
alovirus (A01pp65YSEH, and A02pp65NLVP), we detected 
(Additional file 1: Figure S1A) the highest binding affin-
ity for A01PentonSTDV (FI 0.13), A01PentonSSDI (FI 0.11), 
A02PentonILHT (FI 1.29) and A02PentonALGI (FI 1.29) 
by in vitro T2 peptide binding assay. The peptide bind-
ing results generated by computer and in vitro analyses 
were comparable. Because immunodominant peptides 
bound to HLA molecules were shown to be more sta-
ble than non-immunogenic peptides [33, 37], we further 
investigated the peptide-HLA class I stability of peptides 
of the database-available HLA types A*01, A*02, and 
A*03 using the CBS NetMHCstab algorithm (Table  2). 
HLA class I peptide complexes with a predicted half-life 
(t1/2) > 2 h are defined as very stable [33]. This criterion 
was met by 7/14 epitopes (50  %) restricted to HLA-
A*01, -A*02, and -A*03, including two highly stable 
(HS, t1/2 ≥  6 h) and five weakly stable (WS, t1/2 ≥  2 h) 
epitopes.
Identification of specific IFN-γ responses to the HAdV 
peptide candidates
Our analysis of specific memory T-cell responses to the 
control antigens HAdV5Hexonpp, HAdV5Pentonpp, and 
A01HexonTDLG revealed high response rates in healthy 
donors (Fig.  2a) and HAdV-infected HSCT recipients 
(Fig. 2b). A total of 19 peptide candidates were selected 
and analyzed by IFN-γ EliSpot for their capacity to 
induce HAdV-specific T-cell responses. Seven elicited a 
specific T-cell response, defined by a cut-off of ≥5  spw 
(Table 1). The response rates ranged from 16.7 to 65.8 % 
(Fig.  2a). Pre-classification of peptide candidates into 
Table 2 Prediction results for the investigated HAdV epitope candidates
Prediction results for 19 epitope candidates (plus one reference epitope, A01HexonTDLG) predicted for frequent HLA class I alleles and clinically relevant HAdV types 
using three different prediction tools (SYFPETHI, BIMAS, and NetChop). Epitope candidates were selected with respect to their predicted HLA binding affinity (BL 
binding level) and peptide-HLA complex stability (SL stability level). Epitopes were classified as weak binders (WB threshold 500 nM) or strong binders (SB threshold 
50 nM) with either weak stability (WS threshold 2 h) or high stability (HS threshold 6 h) according to the predicted scores.
Pre-classified immunodominant peptide candidates are highlighted in italic
a Estimated half-time (t1/2) of dissociation (in hours)
b Estimated peptide binding affinity to HLA alleles as IC50 value (in nM)
c Estimated stability of peptide-MHC I complexes as IC50 value (in nM), and IC50 = half-maximum inhibitory concentration
Abbreviation Prediction score
SYFPEITHI [score] BIMAS [rank] NetChop
NetMHCcons [BL]
b NetMHC [BL]b NetMHCstab 
[SL]c, Ta1/2
A01HexonTDLG 20 0.125 [134] 11052.58 13301 0.63
A01HexonTNDQ 28 6.25 [11] 677.84 [SB] 1182 2.08 [WS]
A01HexonQNDP 27 125 [1] 1691.19 [WB] 3899 2.97 [WS]
A02HexonTLLY 27 3432.948 [1] 3.25 [SB] 3 [SB] 14.1 [HS]
A02HexonTLAV 25 69.552 [15] 649.13 513 1.09
B08HexonGLRY 32 160 [1] 42.02 [SB] 40 [SB] –
B08HexonDLQD 26 24 [2] 2339.71 3791 –
A01PentonSTDV 35 312.5 [1] 5.9 [SB] 7 [SB] 4.86 [WS]
A01PentonSNDS 28 6.25 [8] 953.12 [WB] 2784 1.74
A01PentonSSDI 33 187.5 [1] 8.07 [SB] 9 [SB] 4.23 [WS]
A01PentonLTDH 21 6.25 [9] 43.65 [SB] 30 [SB] 1
A02PentonILHT 23 271.948 [2] 16.75 [SB] 18 [SB] 5.72 [WS]
A02PentonALGI 23 69.552 [5] 69.13 [WB] 64 [WB] 7.77 [HS]
A02PentonGNIP 20 >20 16673.41 17051 0.5
A03PentonVLES 25 9 [4] 1073.58 1099 0.7
A03PentonLLPG 23 3 [5] 27426.93 21324 0.22
B08PentonNTKY 29 80 [2] 39.6 [SB] 26 [SB] –
B08PentonDSKG 28 160 [1] 755.3 [WB] 799 –
B08PentonLTKD 32 120 [2] 2134.13 4050 –
B08PentonDSKK 28 160 [1] 130.88 [SB] 80 [WB] –
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Fig. 2 Screening of HAdV‑specific T‑cell responses by IFN‑γ EliSpot. a IFN‑γ EliSpot was performed in 64 healthy donors to evaluate specific T‑cell 
responses to overlapping HAdV hexon (HAdV5Hexonpp) and penton peptide pools (HAdV5Pentonpp), four hexon‑derived peptides (A01HexonTDLG, 
A01HexonTNDQ, A02HexonTLLY, B08HexonDLQD), and four penton‑derived peptides (A01PentonSTDV, A02PentonILHT, B08PentnDSKG, B08PentonDSKK). b 
IFN‑γ EliSpot analysis of 26 HAdV‑infected HSCT recipients for specific T‑cell responses to overlapping HAdV hexon (HAdV5Hexonpp) and penton 
peptide pools (HAdV5Pentonpp) and to the peptides A01HexonTDLG, A02HexonTLLY and A01PentonSTDV. T‑cell responses were assessed in HAdV‑
infected post‑transplant patients. The highest T‑cell response is shown for each tested patient. PBMCs cultured with medium alone or in the pres‑
ence of 1 µg/ml staphylococcal enterotoxin B (SEB) served as negative and positive controls, respectively. IFN‑γ EliSpot results are expressed as the 
number of IFN‑γ spots per well (spw). The cut‑off value for a positive response was ≥ 5 spw in healthy donors and ≥2 spw in HAdV‑infected HCST 
recipients. Only data and mean frequencies from positive responder are shown. Asterisks indicate statistically significant differences between the 
antigens (*p < 0.05, **p < 0.01, ***p < 0.001)
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non-immunodominant or immunodominant was per-
formed according to the number of responders (≥20 %).
The A01HexonTNDQ was pre-classified as non-
immunodominant (16.7  % responder), whereas pep-
tides B08HexonDLQD, A02PentonILHT, B08pentonDSKG, 
B08PentonDSKK (n = 4, Table 1) were pre-classified as low 
immunodominant. T cells from ≥50 % of healthy donors 
recognized the peptides A02HexonTLLY and A02Penton-
STDV and were therefore pre-classified as highly immu-
nodominant. The mean number of IFN-γ+ spots ranged 
from 6 to 17  spw, and was highest for A02HexonTLLY 
(17 spw) and A01PentonSTDV (mean 10 spw).
The response to the hexon control antigens (HAd-
V5Hexonpp: 81.3  % responder, 37 spw; A01HexonTDLG: 
55.6  % responder, 38  spw) was comparably high in 
healthy donors. For HAdV5Pentonpp we found a positive 
T-cell response in 75 % of donors (14 spw) and T-cell fre-
quencies which were not significantly higher compared 
to the new A01PentonSTDV epitope.
In HAdV-infected HSCT patients, the immunogenic-
ity of both peptide epitopes A02HexonTLLY and A01Pen-
tonSTDV was further assessed to confirm their clinical 
relevance (Fig.  2b). Specific T-cell responses against the 
control antigens HAdV5Hexonpp (45 spw) and A01Hex-
onTDLG (17 spw) were found in 100  % of patients. All 
HLA-A*02-positive patients (5/5) developed a HAdV-
specific T-cell response against A02HexonTLLY (≥2  spw, 
5  spw). For A01PentonSTDV we found a positive T-cell 
response in 5/6 (83.3 %) of patients (9 spw), while 24/26 
(92.3 %) of all patients developed a HAdV5Pentonpp-spe-
cific T-cell response (21 spw).
Comparing both overlapping peptide pools, T-cell 
responses to hexon were significantly higher (healthy 
donors: 2.6-fold, patients: 2.1-fold) than those to penton. 
Furthermore, T cells from most donors and patients rec-
ognized HAdV5Hexonpp and A01HexonTDLG at higher 
frequencies than A02HexonTLLY, but showed no signifi-
cant frequency differences between HAdV5Pentonpp and 
the peptide candidate A01PentonSTDV.
Validation of pre-classified immunodominant adenoviral 
CTL epitopes
To find the optimal concentrations of the six pre-classified 
immunodominant peptides (Table  1, highlighted in italic) 
for T-cell immunoassays, we determined the sensitizing pep-
tide concentration required to elicit 50 % of maximal T-cell 
responses (SD50) using the IFN-γ EliSpot assay (Fig. 1; Addi-
tional file 1: Figure S1B). The SD50 ranged from 5 to 10 µg/
ml for B08HexonDLQD (n = 2) and B08PentonDSKG (n = 2), 
and from 10 µg/ml to 50 µg/ml for A02HexonTLLY (n = 3), 
A01PentonSTDV (n  =  2), A02PentonILHT (n  =  2), and 
B08PentonDSKK (n  =  2). Therefore, T-cell immunoassays 
were performed at a final peptide concentration of 10 µg/ml.
Highly proliferative capacity of peptide‑induced 
HAdV‑specific T cells
The proliferation profile of HAdV-specific T cells in 
response to A02HexonTLLY and A01PentonSTDV (n  =  5, 
Fig.  3a) was assessed 7  days after in  vitro stimulation. 
A mean frequency of 33.3  % CFSElowCD3+ (A02Hex-
onTLLY: mean 45.5 %, A01PentonSTDV: mean 21.1 %) and 
CFSElowCD3+CD8+ T cells (A02HexonTLLY: mean 19.4 %, 
A01PentonSTDV: mean 47.2  %) was detected, while 
A01PentonSTDV-stimulation resulted in 2.4-fold higher 
CD3+CD8+ T-cells proliferation (p < 0.05) than A02Hex-
onTLLY. The other peptide candidates also resulted in high 
T-cell proliferation capacities (Table 1; Additional file 2: 
Figure S2): B08HexonDLQD induced the highest prolif-
erative capacity of CD3+ T cells (mean 52.9  %), while 
B08PentonDSKK induced the highest CD3+CD8+ T-cell 
proliferation (mean 39.1 %).
Differentiation phenotype of HAdV peptide‑specific CD8+ T 
cells
After in  vitro stimulation, A02HexonTLLY- and A01Pen-
tonSTDV-specific CD8+ T cells displayed a phenotype 
characterized by a loss of CD45RA (Fig.  3b). Pheno-
typic analysis revealed that the proportion of CD8+ 
T-cell subsets in response to stimulation with A02Hex-
onTLLY and A01PentonSTDV significantly changed dur-
ing T-cell expansion. The highest phenotypic changes 
were observed in CD8+ T-cell responses to A01Pen-
tonSTDV, with a significant decrease in TN (mean 44.1 % 
to 25.1 %, p < 0.001) and TEMRA (mean 23.9 % to 9.8 %, 
p < 0.05), and significantly increased frequencies of TCM 
(mean 10.8 % to 22.9 %, p < 0.05) and TEM (mean 21.2 % 
to 42.3  %, p  <  0.01  %). Stimulation with A02HexonTLLY 
also resulted in a significant increase in CD8+ TEM (mean 
24.6 % to 32 %, p < 0.05 %). Higher frequencies of cyto-
toxic A02HexonTLLY-specific (mean 5-fold) and A01Pen-
tonSTDV-specific CD8+ T cells (mean 11-fold) were 
further detected after T-cell expansion using the respec-
tive pentamers (Fig.  3b). Expansion of HAdV-specific 
CD8+ T cells in response to the other peptide candidates 
(Additional file 2: Figure S2B) resulted in a comparable, 
differentiated phenotype with decreased frequencies 
of TN (mean 1.2-fold) and TEMRA (mean 1.7-fold) and 
increased frequencies of TCM (mean 1.5-fold) and TEM 
(mean 1.3-fold).
Cytotoxic capacity of expanded HAdV peptide‑specific CD8+ 
T cells
The cytotoxic activity of expanded HAdV-specific CTLs 
against the six pre-classified immunodominant peptide 
candidates (Table 1, highlighted in italic) was analyzed to 
evaluate their functionality and specificity. Comparison 
of peptide candidates A02HexonTLLY and A01PentonSTDV 
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Fig. 3 Analysis of HAdV‑specific T‑cell responses to the immunodominant epitopes A02HexonTLLY and A01PentonSTDV in healthy donors. HAdV‑
specific T cells induced by A02HexonTLLY and A01PentonSTDV were characterized in relation to a proliferative capacity of peptide‑specific T cells 
within CD3+ and CD3+CD8+ T‑cell populations b phenotype and frequency of HAdV‑specific CD8+ T cells, (C) cytotoxicity of CD8+ T cells by 
multicolor flow cytometry. a PBMCs from healthy donors were labeled with carboxyfluorescein succinimidyl ester (CFSE) and stimulated over 7 days 
with A02HexonTLLY or A01PentonSTDV, respectively and analyzed for the frequency of viable proliferative CD3
+ and CD3+CD8+ T cells (CFSE low). The 
proliferative capacity of unstimulated CSFE‑labeled PBMCs (negative control) was subtracted from the values for peptide‑stimulated PBMCs. Results 
of independent experiments (n = 5) are expressed as mean ± SD. b Frequency of A02HexonTLLY‑ and A01PentonSTDV‑specific CD8+ T cells and their 
four subsets—naïve (TN), central (TCM), effector memory (TEM), and terminally differentiated effector memory (TEMRA) T cells—from healthy donors 
before (day 0) and after two restimulation cycles (day 14), including dot plots for phenotype and multimer+CD8+ T cells of one representative 
donor (upper right). Results of independent experiments (n = 3) are expressed as mean ± SD. c Cytotoxic activity of expanded A02HexonTLLY‑ and 
A01PentonSTDV‑specific T cells from healthy donors (day 14, effector cells, E) was analyzed in five‑hour cytotoxicity assays using CFSE‑labeled pep‑
tide‑loaded/unloaded PBMCs as target cells (T). Effector T cells were co‑cultured with target cells at an E:T ratio of 10:1, 30:10, or 60:1, respectively. 
Basal cytotoxic activity of effector T cells induced by A02HexonTLLY or A01PentonSTDV against the unloaded target cells was subtracted from the 
cytotoxic T‑cell values against peptide‑loaded PBMCs. Results (n = 2) are expressed as the mean percentage of target cell lysis ± SD. Asterisks shown 
in the figure indicate statistically significant differences between T‑cell proliferation, phenotype and cytotoxicity in response to A02HexonTLLY‑ and 
A01PentonSTDV (*p < 0.05, **p < 0.01, ***p < 0.001, SD, standard deviation)
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(Fig.  3c) showed that the highest cytotoxicity occurred 
at an E:T ratio of 60:1 for A02HexonTLLY-specific CTLs 
(8.2 ± 0.4 %). The cytotoxic capacities in response to the 
other candidates (Additional file 2: Figure S2C) were sim-
ilarly high, while the highest percentage of specific target 
lysis was detected for B08HexonDLQD-specific CTLs at an 
E:T ratio of 60:1 (10.6 ± 8.5 %).
Increased expression of IFN-γ (cytotoxic marker) and 
CD107a (degranulation marker) further verified the 
peptide-specific function and specificity of activated 
CD8+ CTLs. A02HexonTLLY and A01PentonSTDV gener-
ated the highest IFN-γ+ T-cell responses (Fig. 2a), while 
B08PentonDSKG (18.7  %) and A01PentonSTDV (15.8  %) 
induced the highest frequencies of CD107a-positive 
CD3+CD8+ T cells (Additional file 2: Figure S2D). Com-
pared to unstimulated CD3+CD8+ T cells, the highest-
fold increases in CD107a-positive CD3+CD8+ T cells 
was observed in response to the peptides A02Hex-
onTLLY (5.7-fold increase) and B08HexonDLQG (3.3-fold 
increase).
A01PentonSTDV and A02HexonTLLY induce the expansion 
of HAdV‑specific CD8+ CTLs
Healthy donors were tested for precursor frequen-
cies of circulating A02HexonTLLY- and A01Pen-
tonSTDV-specific CD8+ T cells and in  vitro T-cell 
expansion efficiency (Fig.  4a). The frequencies of 
A02HexonTLLY-(0.12  ±  0.08  %, p  <  0.01) and A01Pen-
tonSTDV-(0.11 ± 0.05 %, p < 0.001)  specific CD8+ T-cell 
precursors in freshly isolated PBMCs were significantly 
lower than the frequencies of circulating A01HexonTDLG-
specific CD8+ T cells (0.46 ± 0.48 %, positive controls); 
however, A01PentonSTDV and A01HexonTDLG resulted in 
significant differences after in vitro expansion (p < 0.05). 
The numbers of responders in freshly isolated PBMCs 
(A01HexonTDLG: 66.7 %, A02HexonTLLY: 64.3 %, A01Pen-
tonSTDV: 63.6  %) were comparable to those detected by 
IFN-γ EliSpot. After in  vitro expansion, significantly 
higher frequencies of HAdV-specific CD8+ T cells were 
detected in response to all investigated HAdV peptides; 
rates ranged from 0.32 to 0.94  %, representing a 2.1 to 
3.4-fold increase as compared to freshly isolated PBMCs.
Furthermore, the frequencies of antigen-specific CD8+ 
T cells against A02HexonTLLY and A01PentonSTDV in 
peripheral blood from HAdV-infected patients were 
monitored to validate their clinical relevance (Fig.  4b). 
Results obtained by pentamer staining correlated with 
those from the EliSpot assay. Increased frequencies of 
HAdV-specific CD8+ T cells against A01HexonTDLG 
(mean 2.46  %, n  =  6), A02HexonTLLY (mean 1.64  %, 
n =  5) and A01PentonSTDV (mean 2.19  %, n =  6) were 
detected with no significant differences between the 
a
b
Fig. 4 Frequencies of HAdV‑specific T cells in healthy donors 
and HAdV‑infected HSCT recipients. Percentage of HAdV‑specific 
CD3+CD8+ T cells as detected by pentamer staining. a PBMCs from 
healthy donors were analyzed for A01HexonTDLG‑, A02HexonTLLY‑ 
and A01PentonSTDV‑specific CD3
+CD8+ T cells before (day 0) and 
after stimulation with the peptides A01HexonTDLG, A02HexonTLLY 
or A01PentonSTDV, respectively (day 7). Frequencies of A01Hex‑
onTDLG‑, A02HexonTLLY‑ and A01PentonSTDV‑specific CD8
+ T cells, as 
detected by pentamer staining, are expressed as mean frequencies 
of HAdV‑specific CD3+CD8+ T cells. b T‑cell responses were assessed 
in HAdV‑infected patients. Highest frequencies of A01HexonTDLG, 
A02HexonTLLY‑, and A01PentonSTDV‑specific CD8
+ T cells as detected 
by pentamer staining, were shown for each patient and are expressed 
as mean frequencies of HAdV‑specific CD3+CD8+ T cells. CD8+ T cells 
were stained with PE‑labeled pentamers. The results of independ‑
ent experiments are expressed as mean HAdV‑specific CD3+CD8+ 
T‑cell frequencies. Asterisks indicate statistically significant differences 
between the HAdV peptides (*p < 0.05, **p < 0.01, ***p < 0.001)
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three peptide epitopes. The generated pentamer results 
emphasize the differentiated CD45RAneg phenotype of 
expanded peptide-specific CTLs.
High enrichment efficiency of A02HexonTLLY- 
and A01PentonSTDV-specific T cells
The function of in  vitro expanded HAdV-specific T 
cells was evaluated by CSA in order to determine how 
quickly and strongly HAdV-specific T cells secreted 
IFN-γ in response to A02HexonTLLY and A01Penton-
STDV, respectively. IFN-γ+ T-cell populations in healthy 
donors were investigated by multicolor flow cytometry 
before and after enrichment (Fig. 5; Additional file 3: Fig-
ure S3). According to the peptide-specific CD3+ T-cell 
frequency in the CSA fraction before enrichment (“Ori-
gin”), donors were classified as either weak responders 
(WR < 0.3 % IFN-γ+CD3+ T cells, A02HexonTLLY: n = 2, 
A01PentonSTDV: n = 3) or strong responders (SR, > 0.3 % 
IFN-γ+CD3+ T cells, n = 2). The “Origin” CSA fraction 
contained 0.21 ±  0.13  % (WR) and 1.89 ±  0.78  % (SR) 
IFN-γ+CD3+ T cells, which could be enriched with a 
mean purity of 12.6 ± 8.22 % in WR and 76.7 ± 8.47 % in 
SR, including 11.0 ± 12.3 % (WR) to 86.6 ± 4.59 % (SR) 
of IFN-γ secreting CD3+CD8+ T cells (Fig. 5). The mean 
frequency of A01PentonSTDV-specific IFN-γ+CD3+ T 
cells before (0.17 ± 0.12 % WR and 0.85 ± 0.35 % SR) and 
after enrichment (3.97 ± 1.43 % WR and 54.58 ± 11.30 % 
SR) was 1.5-fold lower than for A02HexonTLLY, whereas 
the frequency of IFN-γ+CD3+CD8+ T cells was com-
parable (2.60 ±  0.62  % WR and 90.78 ±  2.67  % SR) to 
A02HexonTLLY. The low enrichment efficiency of donors 
classified as weak responders reflects the low precur-
sor frequency of antigen-specific CTLs (A02HexonTLLY: 
0.19  %, A01PentonSTDV: 0.30  %), as determined by pen-
tamer staining, which may lead to a low binding affinity 
of IFN-γ-secreting T cells in the CSA. In this context, 
starting with an antigen-specific CD8+ T-cell frequency 
>0.3  % (A02HexonTLLY: 0.82  %, A01PentonSTDV: 5.37  %, 
SR) resulted in the enrichment of highly pure IFN-γ-
secreting T cells.
Discussion
Adoptive T-cell immunotherapy has become a promis-
ing treatment option for patients with adenoviral infec-
tions after transplantation since these cells were shown to 
play a pivotal role in viral control and clearance. Accurate 
monitoring of the viral load and antiviral T-cell immu-
nity is of great importance to effectively treat emerging 
or overt HAdV infections in post-transplant patients. 
Moreover, analysis of the specific T-cell repertoire in 
potential T-cell donors is essential to identify the most 
suitable donors for adoptive transfer and may prove 
helpful for donor choice in patients with pre-transplant 
viral conditions.
In this study, we assessed the immunogenicity of 19 
potential adenoviral CTL epitopes identified by reverse 
immunology. Various epitope prediction algorithms 
were employed to pre-screen for immunodominant 
CTL epitopes. We found that the prediction accuracy 
for CD8+ T-cell epitopes was improved by combin-
ing different algorithms for peptide binding affinity and 
pMHC complex stability. Because prediction results do 
not reflect one-to-one correlation with experimental 
data, we validated the immunogenicity of the predicted 
epitopes in  vitro. IFN-γ EliSpot evaluation of peptide-
specific T-cell responses in PBMCs from healthy donors 
resulted in the pre-classification of four CTL epitopes 
as low immunodominant (response ≥20  %) and two as 
high immunodominant (response ≥50 %) (Table 1, high-
lighted in italic). Immunodominance of these six candi-
dates was verified by T-cell immunoassays and T-cell 
immunomonitoring in HAdV-infected HSCT patients, 
which delineated the significance of the identified CD8+ 
T-cell epitopes in  vivo. Guenther et  al. identified the 
naturally presented HAdV epitopes LTDLGQNLLY and 
VPATGRTLVL [19], for which we obtained high predic-
tion scores. These results underline the high prediction 
accuracy of HLA-class I epitopes obtained by the allele-
specific prediction algorithms utilized in the present 
study.
Description of the first identified penton-derived 
immunodominant CD8+ T-cell epitopes
Here, we were focused on the identification of peptide 
epitopes from HAdV penton, a major capsid protein. 
The penton base interacts with the other major capsid 
proteins (hexon and fiber) and is known to be involved 
in adenovirus cell entry [38]. Despite the variability of 
clinically relevant HAdV types, the penton sequence is 
composed of highly conserved regions and short hyper-
variable loops, similar to hexon [39].
Identification of immunodominant T-cell epitopes 
from these conserved regions represents an attractive 
approach to induce antiviral T cells that are cross-reac-
tive with several potentially lethal HAdV types. Previous 
studies have demonstrated sequential or concomitant co-
infections with different HAdV types in immunocompro-
mised patients, which seem to result in the generation of 
recombinant HAdV types [6, 40, 41]. In the present and 
a previous study we identified HAdV types 1, 2, and 31 
as the predominant pathogens in most pediatric patients 
with severe HAdV disease [7]. In our present study, 10 
of 26 post-transplant patients were infected with type 31 
of HAdV species A, and three of them were co-infected 
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Fig. 5 Enrichment of functional A01PentonSTDV‑ and A02HexonTLLY‑specific T cells by IFN‑γ‑based cytokine secretion assay. HAdV‑specific T cells 
were induced by stimulating PBMCs from healthy donors with A02HexonTLLY, A01PentonSTDV, HAdV5Hexonpp or HAdV5Pentonpp, respectively. 
Stimulated T cells were isolated using IFN‑γ‑based cytokine secretion assay. The frequency of IFN‑γ‑secreting cells among CD3+, CD3+CD4+ and 
CD3+CD8+ T cells in the CSA fractions before (“Origin”) and after (“Eluate”) enrichment were determined by multicolor flow cytometry. The results 
of the peptide‑specific T‑cells enrichment process for weak responders (WR, <0.3 % IFN‑γ+CD3+ T cells) and strong responders (SR, >0.3 % IFN‑
γ+CD3+ T cells) are shown as mean ± standard deviation (SD)
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with type 2 of HAdV species C. The peptide epitopes 
identified in this study are shared among HAdV types 
and may thus facilitate viral clearance even in patients 
suffering from co-infection with different strains.
For the first time we identified three low immunodomi-
nant peptide epitopes (A02PentonILHT, B08PentonDSKG, 
B08PentonDSKK) and one high immunodominant peptide 
epitope (A01PentonSTDV) of the major HAdV capsid pro-
tein penton. Sequences of all identified immunodominant 
epitopes were highly conserved among the clinically rele-
vant HAdV species C, with the exception of A31-derived 
B08PentonDSKG (DSKGRSYNL), which only differs in 
one amino acid from the peptide B08PentonDSKK (DSK-
KRSYNL) but is composed of the same amino acids at 
the conserved anchor positions P2 and P9. The sequence 
of the newly identified A01PentonSTDV is located between 
amino acid positions 76 and 84 of the penton protein of 
HAdV types 1, 2, and 5. Immune responses to the whole 
adenovirus, including the hexon protein, were dominated 
by memory CD4+ T cells. Interestingly, A01PentonSTDV 
was identified as a strong inducer of functional CD8+ 
CTLs (11-fold increase in A01PentonSTDV-specific CD8+ 
CTLs), which could be efficiently enriched to a high fre-
quency (90.4 % recovery), comparable to the HAdV5Pen-
tonpp peptide pool (96.9  % recovery). In  vitro expanded 
A01PentonSTDV-specific CD8+ T cells showed a differ-
entiated CD45RAneg T-cell phenotype, with TEM proved 
to be essential for effective clearance of and protection 
against HAdV infections, while TCM demonstrated to 
be involved in preventive long-term immunity [13]. The 
immunogenicity of all four pre-classified immunodomi-
nant penton epitopes was verified by antiviral T-cell 
monitoring and in  vitro T-cell immunoassay in healthy 
donors and patients.
Evaluation of hexon-specific T-cell responses induced 
by the predicted CTL epitopes
In healthy donors, coordinate responses of hexon-spe-
cific CD4+ and CD8+ T cells were demonstrated to con-
tribute to the control of HAdV infections, which persist 
as memory T cells [21]. Most hexon-derived epitopes are 
CD4 restricted [20, 22, 23]. We aimed to identify novel 
hexon-derived CD8+ T-cell epitopes by evaluating the 
immunogenic potential of six predicted CD8+ T-cell 
epitopes. Overall, we detected HAdV-specific T-cell 
responses to 3/6 predicted peptide candidates in healthy 
donors. B08HexonDLQD was thus pre-classified as a low 
immunodominant (≥20 % response) and A02HexonTLLY 
[13, 22, 23] as a high immunodominant CTL epitope 
(≥50  % response). The immunogenicity of both candi-
dates was verified by T-cell monitoring and in vitro T-cell 
immunoassay. In accordance to already published data 
(Table 1), we found no or only minimal T-cell responses 
to the peptide candidates A01HexonTNDQ [21], A02Hex-
onTLAV [13], and B08HexonGLRY [20]. In  vitro expanded 
functional A02HexonTLLY-specific CTLs showed a high 
proliferative and cytotoxic capacity and displayed a 
CD45RAneg differentiated phenotype, which could be 
efficiently enriched to a significantly high frequency 
(85 % recovery), comparable to the HAdV5Hexonpp pep-
tide pool (95.5 % recovery).
Olive et  al. demonstrated that additional three resi-
dues at each end of the immunodominant peptide Hex-
onTLLY (15-mer peptide) resulted in a stronger CD4+ 
T-cell response. In addition, a lower peptide concentra-
tion for in vitro T-cell activation was required compared 
to the nonamer, indicating that the 15-mer peptide is an 
optimal CD4+ T-cell epitope [22, 23]. Guether et al. iden-
tified the decamer of the known immunodominant HLA-
A01-restricted hexon-derived peptide (A01HexonTDLG, 
LTDLGQNLLY) as a naturally presented T-cell epitope 
that induces peptide-specific T cells with a higher prolif-
erative, cytotoxic, and IFN-γ-producing capacity than T 
cells specific for the shorter peptide TDLGQNLLY [19]. 
Therefore, we will evaluate the immunogenic potential of 
longer peptides from the novel identified low immuno-
dominant B08HexonDLQD peptide in a future study.
Comparison of HAdV-specific T-cell repertoires in healthy 
donors and HSCT recipients
Clinical relevance of the identified high immunodomi-
nant CTL epitopes A02HexonTLLY and A01PetonSTDV 
was further assessed in HAdV-infected HSCT recipi-
ents, compared to healthy donors and correlated to T-cell 
responses induced by HAdV5Hexonpp, HAdV5Pentonpp, 
and the immunodominant A01HexonTDLG. As expected, 
the majority of donors and patients had HAdV-specific 
T cells against hexon and penton, and the frequency of 
hexon-specific T cells was higher than that of penton-
specific T cells in both cohorts. More than 50  % of all 
tested donors and patients had HAdV-specific T cells 
against A02HexonTLLY, but at an up to 2.2 (donors) to 
ninefold (patients) lower frequency than the investigated 
control antigens HAdV5Hexonpp and A01HexonTDLG. 
For this reason, A02HexonTLLY can be classified as a 
high immunodominant CTL epitope but, as mentioned 
before, it has a lower immunogenic potential compared 
to the known HAdV5Hexonpp and A01HexonTDLG, as 
underlined by the higher immunogenicity of the 15-mer 
peptide DEPTLLYVLFEVFDV [22]. Interestingly, the 
immunogenic potential of A01PentonSTDV, the novel 
penton-derived CTL epitope, was comparable to that 
of HAdV5Pentonpp in healthy donors and patients. This 
finding indicates that A01PentonSTDV is a major immu-
nodominant penton-derived CTL epitope. In infected 
HSCT recipients we detected higher T-cell responses to 
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the A01PentonSTDV than to the hexon-derived A02Hex-
onTLLY, which was the reverse in healthy donors. These 
data indicate that penton-specific T cells might be essen-
tial for viral control. Future studies including monitoring 
of T-cell functionality and specificity should be done to 
get more inside into the interplay between hexon- and 
penton-specific T cells in the first line of defense and/or 
long-term protective immunity against HAdV.
Peptide-specific T-cell precursor frequencies and limits 
of detection
Low frequencies of circulating HAdV-specific T-cell pre-
cursors in peripheral blood make it difficult to detect 
HAdV-specific T cells, which can lead to false-nega-
tive results [36]. We were able to detect specific T-cell 
responses to the peptide epitopes A02HexonTLLY and 
A01PentonSTDV directly in freshly isolated PBMCs from 
healthy donors by IFN-γ EliSpot, albeit at quite low fre-
quencies (A02HexonTLLY: 17 spw, A01PentonSTDV: 10 
spw). Interestingly, the number of responders after pep-
tide-restimulation was unchanged, indicating that no 
false-negative results were obtained in freshly isolated 
PBMCs compared to peptide-restimulated cells and that 
all tested donors were correctly identified as responders 
and non-responders. However, evaluation of A02Hex-
onTLLY and A01PentonSTDV by pMHC multimer staining 
indicates the need for antigen-dependent T-cell expan-
sion to avoid overlooking effector function of peptide-
induced CTLs with very low precursor frequencies. 
Pentamer staining of freshly isolated PBMCs yielded 
false-negative results in 14.3  % A02HexonTLLY-respond-
ers and 9.1  % of A02PentonSTD-responders. Pentamer 
staining with in  vitro stimulated cells resulted in more 
accurate identification of positive responders as a clearly 
defined peptide-specific CD8+ T-cell population with up 
to 3.3-fold higher frequencies. In this context, the highly 
sensitive IFN-γ EliSpot assay is a suitable technology for 
the detection of low precursor frequencies of circulating 
HAdV-specific T cells in peripheral blood. Conversely, 
for unambiguous identification of responders and non-
responders by pentamer staining, we recommend short 
in  vitro stimulation. The enrichment efficiency of anti-
gen-specific T cells via CSA was further affected by the 
percentage of HAdV-specific T cells. The enrichment 
efficiency of A02HexonTLLY- and A02HexonTLLY-specific 
CD3+ T cells was lower (purity < 13 %) when the starting 
frequency was <0.3  %, whereas a high enrichment effi-
ciency was obtained by using starting frequencies >0.3 % 
(<67  % purity). Therefore, short-term expansion proto-
cols for the generation of higher numbers of functionally 
active HAdV-specific T cells, as described by Geyeregger 
et al., are a suitable option to generate sufficient numbers 
of HAdV-specific T cells for adoptive immunotherapy 
[12, 13]. In addition, manufacturing of clinical-grade 
HAdVPentonpp- and HAdVHexonpp-specific T cells in 
combination might be a promising option to provide 
sufficient numbers of effective HAdV-specific T cells 
for the adoptive T-cell transfer in immunocompromised 
patients.
Conclusions
In summary, HAdV-specific T-cell responses to novel 
identified immunodominant CTL epitopes were 
observed in healthy donors, and the in  vivo relevance 
of these identified CTL epitopes, as predicted by com-
puter algorithms, was confirmed in HAdV-infected 
patients.
We describe the first immunodominant adenovirus 
CD8+ T-cell epitopes from the penton, of which A01Pen-
tonSTDV could be classified as the first high immunodomi-
nant CTL epitope discovered to date. HAdV-specific 
T-cell responses to A01PentonSTDV were comparable to 
those to the HAdV5Pentonpp overlapping peptide pool. 
The development of penton-specific T-cell immunity 
in HAdV-infected HSCT recipients suggested that, as 
an immunological target, the penton protein is not sec-
ondary to the hexon protein. Penton-specific T cells, 
particularly CD8+ CTLs, seem to be essential for effec-
tive defense against HAdV. Immunogenicity of the CTL 
epitope A02HexonTLLY was verified according to its prev-
alence in healthy donors and patients. A broad repertoire 
of immunodominant CD4+ and CD8+ T-cell epitopes 
appears to be crucial for improved immunomonitoring by 
means of precise quantitative assessment. This improve-
ment will enhance the efficacy of adoptive immunother-
apy by enabling the timely start of the adoptive transfer 
with the most suitable HAdV-specific T-cell populations.
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